Trial Profile
A randomized controlled study of the efficacy of Tadalafil monotherapy versus combination of Tadalafil and mirabegron for the treatment of overactive bladder (OAB) associated with benign prostatic hyperplasia (BPH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2020
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Tadalafil (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms CONTACT Study
- 05 Feb 2019 Status changed from active, no longer recruiting to completed.
- 18 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2016 New trial record